Multimedia Release -- KYTHERA Biopharmaceuticals Announces

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or "Double Chin"

April 30, 2015 09:00 ET | Source: KYTHERA Biopharmaceuticals, Inc.

WESTLAKE VILLAGE, Calif., April 30, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH), issued a release on Wednesday, April 29, with the headline "Photo Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug." The company is updating this release to include videos, which accompany the release issued yesterday.

Videos accompanying this release are available at:

http://www.globenewswire.com/newsroom/prs/?pkgid=32574

http://www.globenewswire.com/newsroom/prs/?pkgid=32575

http://www.globenewswire.com/newsroom/prs/?pkgid=32576

Media Contact: Ashley Cadle Tel: (310) 463-0143 a.cadle@togorun.com Investor Contact: Heather Rowe Director, Investor Relations Tel: (818) 587-4559 hrowe@kytherabiopharma.com

Multimedia Release -- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drug

KYBELLA(TM) (deoxycholic acid) Injection Significantly Improves Submental Fullness, or "Double Chin"

Tags

Contact Data

Contact